Linghua Wang

机构：The University of Texas MD Anderson Cancer Center, Hunan Provincial Maternal and Child Health Hospital, The University of Texas Health Science Center at Houston · ORCID：0000-0001-9380-0266

发表论文 833 篇 · 总被引 68419 次 · h-index 95

代表论文

• Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis (2026 · Cancer Immunology Research)
• Supplementary Table S8 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
• Supplementary Appendix S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
• Supplementary Table S3 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
• Supplementary Figure S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)
• Supplementary File S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma (2026)